Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29560985 | 0.86 | SMN1; SMN2 (0.44) | RECQLSMN1; SMN2ALDH1A1MAPK1HTT | |
| SCHEMBL4501039 | 0.86 | SMN1; SMN2 (0.44) | RECQLSMN1; SMN2ALDH1A1MAPK1HTT | |
| SCHEMBL377724 | 0.84 | ACHE (0.43) | ALDH1A1MAPK1HTTLMNAKMT2A | |
| SCHEMBL904515 | 0.84 | RECQL (0.54) | RECQLKDM4EACHEHSD17B10CYP3A4 | |
| SCHEMBL7349175 | 0.83 | MAPK1 (0.36) | RECQLSMN1; SMN2ALDH1A1MAPK1HTT | |
| SCHEMBL9608992 | 0.80 | NPC1 (0.39) | SMN1; SMN2ALDH1A1MAPK1HTTLMNA | |
| SCHEMBL29714427 | 0.78 | LOX (0.45) | SMN1; SMN2ALDH1A1MAPK1HTTLMNA | |
| SCHEMBL19755849 | 0.78 | LOX (0.45) | SMN1; SMN2ALDH1A1MAPK1HTTLMNA | |
| SCHEMBL5898063 | 0.78 | HTT (0.41) | SMN1; SMN2ALDH1A1MAPK1HTTLMNA | |
| SCHEMBL6931382 | 0.78 | HTT (0.37) | SMN1; SMN2ALDH1A1MAPK1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903116-A | Cyclin K degrading agent | 杭州阿诺生物医药科技有限公司 | 2024-04-19 | — | — | CN | claimed |
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | claimed |
| EP-4655296-A1 | CBL-B INHIBITORS | Aurigene Oncology Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| EP-4622713-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20240368147-A1 | CYCLIN K DEGRADER | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| WO-2024199069-A1 | POLYARYL-CONTAINING MACROCYCLIC COMPOUND AND USE THEREOF | 浙江养生堂天然药物研究所有限公司 | 2024-10-03 | — | — | WO | disclosed |
| CN-118724916-A | Polyaryl-containing macrocyclic compounds and uses thereof | 浙江养生堂天然药物研究所有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024156938-A1 | CBL-B INHIBITORS | ORION CORPORATION (FI) | 2024-08-02 | — | — | WO | disclosed |
| EP-4382519-A1 | CYCLIN K DEGRADATION AGENT | Adlai Nortye Biopharma Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024112895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024112895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-0944388-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1999041246-A1 | NOVEL CYCLIC SULFONAMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-08-19 | — | — | WO | disclosed |
| US-5891889-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-04-06 | — | — | US | disclosed |
| CN-1205694-A | Quinazoline derivatives | ZENECA LTD (GB) | 1999-01-20 | — | — | CN | disclosed |
| CN-1040327-C | Optionally substituted pyrido [2,3-d] pyrimidine-2,4(1H,3H)-diones and pyrido [2,3-d] pyrimidine-2(1H,3H)-ones | SYNTEX INC (US) | 1998-10-21 | — | — | CN | disclosed |
| WO-1997038665-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| EP-0631580-A1 | PYRIDO 2,3-d]PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-01-04 | — | — | EP | disclosed |
| CN-1078470-A | Any pyrido [2, the 3-d] pyrimidine-2 that replaces, 4-(1H, 3H)-two ketone and pyrido [2,3-d] pyrimidine-2 (1H, 3H)-ketone | SYNTEX A INC (US) | 1993-11-17 | — | — | CN | disclosed |
| WO-1993019068-A1 | PYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1993-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368147-A1 | CYCLIN K DEGRADER | CCNK, CCNI, CDK1 | RECQL 418/4885SMN1; SMN2 2290/4885ALDH1A1 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.